Document is current
Any future updates will be listed below
-
Authors
Katti, Alyna
Vega-Pérez, Adrián
Foronda, Miguel https://orcid.org/0000-0001-9590-9281
Zimmerman, Jill
Zafra, Maria Paz
Granowsky, Elizabeth
Goswami, Sukanya
Gardner, Eric E. https://orcid.org/0000-0002-1552-2675
Diaz, Bianca J. https://orcid.org/0000-0002-5309-1300
Simon, Janelle M.
Wuest, Alexandra
Luan, Wei
Fernandez, Maria Teresa Calvo
Kadina, Anastasia P.
Walker, John A. II
Holden, Kevin https://orcid.org/0000-0002-3091-4124
Lowe, Scott W. https://orcid.org/0000-0002-5284-9650
Sánchez Rivera, Francisco J. https://orcid.org/0000-0002-8466-8563
Dow, Lukas E. https://orcid.org/0000-0001-7048-1418
-
Funding
Funding for this research was provided by:
U.S. Department of Health and Human Services | NIH | National Cancer Institute (R01CA229773, F31-CA247351-02, F31-CA261061, P01-CA087497, 5T32CA160001)
Damon Runyon Cancer Research Foundation (DRG-2343-18)
Howard Hughes Medical Institute (Hanna Gray fellow)
Human Frontier Science Program (LT0011/2023-L)
- License Information
-
More Information
Article History
Received: 14 July 2022
Accepted: 10 July 2023
First Online: 10 August 2023
Competing interests
: L.E.D. is a scientific advisor and holds equity in Mirimus, Inc. L.E.D. has received consulting fees and/or honoraria from Volastra Therapeutics, Revolution Medicines, Repare Therapeutics, Fog Pharma and Frazier Healthcare Partners. S.W.L is an advisor for and has equity in the following biotechnology companies: ORIC Pharmaceuticals, Faeth Therapeutics, Blueprint Medicines, Geras Bio, Mirimus, Inc., PMV Pharmaceuticals and Constellation Pharmaceuticals. S.W.L. acknowledges receiving funding and research support from Agilent Technologies for the purposes of massively parallel oligo synthesis. K.H., A.P.K. and J.A.W. are employees and shareholders of Synthego Corporation.
